Targeting B lymphocyte Signaling to Reprogram Autoimmunity in Type 1 Diabetes

靶向 B 淋巴细胞信号传导以重编程 1 型糖尿病的自身免疫

基本信息

  • 批准号:
    9115911
  • 负责人:
  • 金额:
    $ 2.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The training platform in this proposal focuses on intracellular signaling in B lymphocytes as a new approach to correcting fundamental defects in immune tolerance and to monitoring therapeutic interventions to reprogram islet-destructive immunity. While much work has gone into understanding the intercellular processes that drive T1D, the intracellular cascades that control the destructive responses to islet antigens are undefined. The production of autoantibodies is the earliest available biomarker of autoimmunity, but the mechanisms that permit this breach in immune tolerance remain unknown. While targeting of the whole B lymphocyte pool with rituximab delayed the progression of new-onset T1D, the effect was transient, which may relate to failure to reprogram islet-reactive cells long-term. Like T cells, B cells progress through multiple developmental stages during which they are programmed by antigen contact to be tolerant to self-antigens. This program fails in T1D, which I have hypothesized is due to improper coupling between antigen contact and effector responses during B cell development. In my preliminary studies, I have utilized new approaches in cutting-edge, phosphoflow cytometry to uncover defects in c-Abl signaling in the Transitional 1 (T1) B lymphocyte subset of NOD mice, the benchmark preclinical model of T1D. While the function of c-Abl in oncogenesis has been extensively dissected, its role in the programming of immune tolerance in B cells is largely unknown. In this proposal I will dissect the c-Abl dependent signaling pathways that govern B lymphocyte tolerance mechanisms. I hypothesize that c-Abl modulates the balance between homeostatic expansion and negative selection in the transitional B lymphocyte compartment and that defects in this pathway underlie B lymphocyte selection defects found in autoimmune disease. I will dissect c-Abl mediated pathways that control B lymphocyte homeostasis and selection by applying transgenic, antigen-specific systems and therapeutic targeting of c-Abl pathways for disease modulation (Aim 1). I will extend this analysis of immune signaling to understand how immune function is reprogrammed during disease-modifying therapy using informatics approaches combined with high dimensional mass cytometry (Aim 2). Through this fellowship application, I will develop 1) a detailed understanding of new intracellular pathways of B cell regulation during tolerance induction and 2) my potential as a basic and translational scientist focused on T1D. These training goals will be facilitated by the research plan, by the exceptional team of mentors with expertise in the proposed study design, by completion of the Howard Hughes Certificate Program in Molecular Medicine, and by the resources, facilities, and training plan available through Vanderbilt University.
 描述(由申请人提供):本提案中的培训平台侧重于B淋巴细胞中的细胞内信号传导,作为纠正免疫耐受中的基本缺陷和监测治疗干预以重新编程胰岛破坏性免疫的新方法。虽然许多工作已经进入理解驱动T1 D的细胞间过程,但控制对胰岛抗原的破坏性反应的细胞内级联反应尚未确定。自身抗体的产生是最早可用的自身免疫生物标志物,但允许这种免疫耐受破坏的机制仍然未知。虽然利妥昔单抗靶向整个B淋巴细胞池延迟了新发T1 D的进展,但该效应是短暂的,这可能与长期重编程胰岛反应细胞失败有关。像T细胞一样,B细胞经历多个发育阶段,在此期间,它们通过抗原接触被编程为对自身抗原耐受。这个程序在T1 D中失败了,我假设这是由于B细胞发育过程中抗原接触和效应子反应之间的不正确偶联。在我的初步研究中,我利用尖端的磷酸化流式细胞术的新方法来揭示NOD小鼠的过渡1(T1)B淋巴细胞亚群中c-Abl信号传导的缺陷,这是T1 D的基准临床前模型。虽然c-Abl在肿瘤发生中的功能已被广泛剖析,但其在B细胞中免疫耐受编程中的作用在很大程度上是未知的。在这个建议中,我将剖析的c-Abl依赖的信号通路,管理B淋巴细胞耐受机制。我推测,c-Abl调节稳态扩张和负选择之间的平衡,在过渡B淋巴细胞隔室和缺陷,在这一途径的基础B淋巴细胞选择缺陷的自身免疫性疾病。我将剖析c-Abl介导的途径,控制B淋巴细胞的稳态和选择,通过应用转基因,抗原特异性系统和治疗靶向的c-Abl途径的疾病调制(目标1)。我将扩展这种免疫信号的分析,以了解免疫功能是如何在疾病修饰治疗过程中使用信息学方法结合高维质谱细胞术(Aim 2)重新编程的。通过这项奖学金申请,我将开发1)在耐受诱导过程中B细胞调节的新的细胞内途径的详细了解和2)我的潜力作为一个基础和翻译科学家专注于T1 D。这些培训目标将通过研究计划、具有拟定研究设计专业知识的杰出导师团队、完成霍华德休斯分子医学证书课程以及范德比尔特大学提供的资源、设施和培训计划来实现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher S. Wilson其他文献

A one-week reduced-carbohydrate diet to mitigate iatrogenic peripheral hyperinsulinemia does not improve insulin sensitivity or endothelial function in a randomized, crossover trial in patients with type 1 diabetes
  • DOI:
    10.1186/s12933-025-02658-z
  • 发表时间:
    2025-03-05
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Justin M. Gregory;T. Jordan Smith;Sara H. Duffus;David Brooks;M. Naweed Akbar;Margaret-Anne Huntley;JoAnn A. Gottlieb;Lauren M. LeStourgeon;Christopher S. Wilson;Joshua A. Beckman;Alan D. Cherrington
  • 通讯作者:
    Alan D. Cherrington
Composite metacarpophalangeal joint reconstruction in great toe-to-hand free tissue transfers
  • DOI:
    10.1016/s0363-5023(84)80004-0
  • 发表时间:
    1984-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Christopher S. Wilson;Harry J. Buncke;Bernard S. Alpert;Leonard Gordon
  • 通讯作者:
    Leonard Gordon

Christopher S. Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 2.79万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 2.79万
  • 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 2.79万
  • 项目类别:
    Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 2.79万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10321545
  • 财政年份:
    2020
  • 资助金额:
    $ 2.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了